New research reveals that people who stop using new GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass at a significantly accelerated pace than those who halt conventional diet and exercise plans.
Published data in a major health publication shows that while overweight individuals often shed a large proportion of their body weight while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month upon discontinuation.
"People using such treatments should be aware of the risk of quick rebound weight gain when the therapy is stopped," cautioned expert Dr. Susan Jebb.
Such speed of recovery implies a return to original mass in about a year and a half.
Analyzing Treatments
The research, which examined dozens of studies involving over 9,000 of patients, contrasted the results of the injectable medications with conventional dieting.
Scientists emphasize that people who lose weight through diet and exercise generally have a more gradual creep back—approximately 100 grams monthly—after stopping.
Understanding the Quick Rebound
Doctors propose the way of the drugs is key to understanding the accelerated regain.
These medications imitate a natural hormone called GLP-1, which controls appetite.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production could lead to the system to generate a reduced amount of its endogenous hormone, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' results in hunger is unsuppressed, making overeating far more likely."
A Chronic Condition?
The NHS advise the jabs for individuals with weight-linked medical conditions, alongside recommended lifestyle changes.
Professionals argue that, given the likelihood of weight regain, the treatment should be considered life-long.
This perspective is echoed by drug manufacturers, who state that the findings "emphasize the chronic nature of obesity," similar to managing diseases like high blood pressure.
Patient Testimonies
Individuals who have come off the jabs report a intense resurgence of cravings.
"It was like a switch that goes on and you're instantly ravenous," said a patient.
This difficulty is worsened if users have not established sustainable lifestyle or habit changes during therapy.
Significant Adoption
Figures indicate that millions of people in the UK have used these injections in the last 12 months, with desire remaining high.
- Use is greater among females compared to men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Finally, clinicians caution that while the jabs are effective tools for weight loss, they are not a standalone fix and long-term success likely depends on combined behavioural changes.
